Keybanc analyst Kenneth Zener downgrades Installed Building Prods (NYSE:IBP) from Overweight to Sector Weight.
AIM ImmunoTech Says FDA Meeting Request Has Been Deemed Sufficient For Transfer To FDA’s Division Of Neurology
AIM ImmunoTech Inc. (NYSE:AIM) today announced positive progress with the company's meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as an infusion
